Astex announces Clinical Trial Authorization for novel cancer drug AT7519 and plans for two further new drug filings in the next nine months

Astex announces Clinical Trial Authorization for novel cancer drug AT7519 and plans for two further new drug filings in the next nine months

SuperGen Reports Results of Phase III Rescue Study With Orathecin™ (Rubitecan Capsules) Versus 5-FU in Pancreatic Cancer Patients

SuperGen Reports Results of Phase III Rescue Study With Orathecin™ (Rubitecan Capsules) Versus 5-FU in Pancreatic Cancer Patients

SuperGen Initiates Phase II Combination Trial of Orathecin™ and Gemcitabine in Chemotherapy Naive Pancreatic Cancer Patients

SuperGen Initiates Phase II Combination Trial of Orathecin™ and Gemcitabine in Chemotherapy Naive Pancreatic Cancer Patients